1 year DiGAs in Germany – Garden of Eden?

One year ago, a special reimbursement process for digital health applications (so-called DiGAs) was implemented in Germany. Until June 2021, 15 DiGAs have been approved by the authority BfArM and the first one is starting price negotiations now.
DiGA experts Dr. Stefan Walzer and Ariane Schenk (Bitkom Health) will discuss the following items:

  • Process for DiGAs in Germany
  • Success factors for DiGAS
  • Price negotiation frame for DiGAs
  • Outlook into the future, e.g. DiPAs

Register now for free!

The end in drug price negotiations in Germany? The “mystic” arbitration board?!

Within the German pharmaceutical market access process a core component is the price negotiation which follows in the second part of the evaluation. Negotiations will be conducted between pharmaceutical company and the Head Association of the Statutory Health Insurance Funds. In case no agreement is reached, each party could call the arbitration board which could then come up with a price agreement. The presenters will discuss the decisions of the last 10 years and potential implications. Furthermore, Prof. Wasem as the former head of the arbitration board will discuss the view of it and his experience.

Register now!

Access to German hospitals – pathways to follow

The pathway to German hospitals for medical devices, digital health applications and drugs can be straight forward in Germany. However, in the meantime there are various pathways available including the famous “NUB” and the newly introduced Hospital Future Act as well as experimental coverage and innovation fund applications. Additionally, investment goods need to differentiate between hospital ownerships.
The presenters, both long-lasting members of the Inpatient committee at the German Health Economic Association, will discuss the various pathways and applicability as well as the correlation to the annual budget negotiations of hospitals and will show the various aspects to consider when planning a launch into the German hospital setting.

Register now!

MArS goes Clubhouse (again) – 10 years AMNOG

After a great webinar on “10 years AMNOG” on Thursday evening, we are happy to announce that the discussions are expanded into the German-speaking community! MArS Market Access & Pricing Strategy GmbH goes (again) to Clubhouse!! The session on April 1 2021 will be recorded and made available afterwards as well – but even better, join us and discuss directly with well-known experts: Dr. Stefan Walzer, Prof. Dr. David Matusiewicz, Bibiane Schulte-Bosse, Dr. Mathias Flume, Heiko Schellhorn, Prof. Dr. Thomas Hammerschmidt – moderation as always by Lutz Vollmer!!

Join us at Clubhouse!!

10 years AMNOG – what have we learnt for drug development and pricing?

10 years ago, the German reimbursement system for drugs changed significantly. The AMNOG including a benefit assessment and price negotiation was launched. Threats were seen, but also opportunities – the AMNOG frame was criticized and in some aspects also changed over time. A learning system – as some say.
The speakers have worked and shaped the AMNOG process also before its implementation and have also been working since the start of it in various roles and on different products. The presentation and discussions will shows the following key aspects:

  • What are key success factors for a optimal AMNOG process?
  • Are there any guidances for clinical development?
  • How is the benefit rating and price negotiation correlated? What are drivers?
  • What can we expect in the future from the AMNOG?

Register now!

MArS goes Clubhouse! Digitalisation in the German health care system!?!

Are DiGAs and the Hospital Future Act sufficient to lead Germany digitally to the top?

Join the discussion at Clubhouse with our co-hosts Ariane Schenk (Bitkom), Prof. Dr. David Matusiewicz (FOM), Timo Frank (Ada Health) and Dr. Mike Christian Papenhoff (BG Klinikum Duisburg) as well as Dr. Stefan Walzer and Lutz Vollmer (both MArS).

#digitalisierung #digitalhealth #digitalhealthcare #clubhouse

The Alpes, cheese, banks – and early paid access for drugs! Wonderland Switzerland?!

The Swiss reimbursement process includes a standard submission of the evidence and a price negotiation in written with the BAG. However, in some circumstances there is a special law which also allows an early access which includes payment / reimbursement for the drug of interest.
Within this free webinar the presenters will discuss…
… the respective law and its application
… the requirements for the law
… dos and don’ts im Prozess
… die importance of physicians and insurance contacts

Register now for the free webinar: Registration

Digital health in Germany – start of a rocket or just a big bluff?

In Germany a new market access & reimbursement pathway has been implemented for health apps in 2020. The DiGA experts Dr. Stefan Walzer will present the current results of the BfArM evaluations and experiences with various DiGA applications. Additionally, Dr. Ulf Maywald, AOK Saxonia, will bring the German payer’s view and their experiences with DiGAs and the process into the discussion.
What you will learn during that webinar:

  • How does the DiGA process look like?
  • What are key success factors within the process with the BfArM?
  • What do German payers want to see in terms of evidence and price anchors?

Register now!

The end of Covid-19 due to vaccines? By when do we have our lives back?

The covid-19 outbreak has had a significant impact on daily life of populations in the last year. Recently three pharmaceutical companies have communicated promising results of their vaccination candidates against Covid-19. Various countries in Europe have implemented vaccination programs or strategies how to set these up. Within the webinar those programs will be assessed utilizing a Covid-19 SEIR model (CovidSIM). The MArS expert team will show you in the webinar:
• Vaccination programs in Europe
• Implication of these programs from a simulation perspective
• An estimation of when the “old” normal might be the “new(set)” normal

The webinar will be held one week before Christmas. The first 24 registrations will receive a German “Gluehwein” as normally available on German Christmas markets.

The potential impact of the 2020 US presidential election on global health care pricing

The expert teams of MArS and PSE will summarize the results of the US presidential election before detailed discussions and finding on the potential health care changes and its global impact will be discussed. Most likely the potential price referencing of US prices to a global country basket will be included as other specific items.

Register now for the free webinar on November 24 2020at 9pm CET / noon PT: Register